Earnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their Forecasts [Yahoo! Finance]
Ocuphire Pharma, Inc. (OCUP)
Company Research
Source: Yahoo! Finance
It was not a great statutory result, with revenues coming in 20% lower than the analysts predicted. Unsurprisingly, earnings also fell seriously short of forecasts, turning into a per-share loss of US$0.46. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. View our latest analysis for Ocuphire Pharma After the latest results, the consensus from Ocuphire Pharma's four analysts is for revenues of US$15.1m in 2024, which would reflect a painful 21% decline in revenue compared to the last year of performance. Losses are forecast to balloon 84% to US$0.74 per share. Before this latest report, the consensus had been expecting revenues of US$28.1m and US$0.0067 per share in losses.
Show less
Read more
Impact Snapshot
Event Time:
OCUP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUP alerts
High impacting Ocuphire Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
OCUP
News
- Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual MeetingGlobeNewswire
- First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery [Yahoo! Finance]Yahoo! Finance
- First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive SurgeryGlobeNewswire
- Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner ViatrisGlobeNewswire
OCUP
Earnings
- 11/13/23 - Beat
OCUP
Sec Filings
- 4/19/24 - Form PRE
- 4/17/24 - Form 8-K
- 4/15/24 - Form 4
- OCUP's page on the SEC website